The role of Adiponectin and Leptin in Colorectal Cancer and Adenoma: a systematic review and meta-analysis.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Leptin*/blood ; Adiponectin*/blood ; Colorectal Neoplasms*/blood ; Colorectal Neoplasms*/epidemiology ; Adenoma*/blood ; Adenoma*/pathology; Humans ; Male ; Risk Factors ; Female

Background: Colorectal cancer ranks as the third most frequently diagnosed cancer globally. Adipokines, including adiponectin and leptin, are believed to play a vital role in the development and progression of tumors. This study aimed to clarify the association between circulating adiponectin and leptin concentrations and the risk of colorectal cancer and adenoma.
Methods: A detailed literature review was conducted in different databases, including Google Scholar, Web of Science, Scopus, and PubMed. Articles measuring serum concentrations of adiponectin and leptin in colorectal adenoma or cancer patients were analyzed. Pooled odds ratios (ORs) and their related 95% confidence intervals (CIs) were estimated through a random-effects meta-analysis.
Results: In total, 30 articles were analyzed. According to the meta-analysis, higher adiponectin concentrations were inversely linked to a reduced CRC risk (OR: 0.85, 95% CI: 0.74-0.96), particularly in men. However, no notable connection was detected between higher leptin concentrations and risk of CRC (OR: 1.12, 95% CI: 0.96-1.31). In subgroup analyses, BMI adjustment reinforced the negative association between higher adiponectin levels and risk of CRC, while insulin adjustment yielded non-significant results. Additionally, higher leptin levels revealed a meaningful relationship with colorectal adenoma risk (OR: 1.39, 95% CI: 1.06-1.84), whereas higher levels of adiponectin were not significantly linked to adenoma (OR: 0.79, 95% CI: 0.46-1.36).
Conclusion: According to this meta-analysis, elevated adiponectin concentrations may play a protective role against CRC, while leptin could potentially contribute to an elevated colorectal adenoma risk. Further studies are required to explore the potential mechanisms underlying adipokine-mediated colorectal carcinogenesis.
(© 2025. The Author(s).)

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

World J Clin Oncol. 2024 Sep 24;15(9):1136-1156. (PMID: 39351451)
Oncology. 2005;68(4-6):454-61. (PMID: 16020976)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Int J Obes (Lond). 2008 Feb;32(2):304-14. (PMID: 17878894)
CA Cancer J Clin. 2024 Sep-Oct;74(5):405-432. (PMID: 38990124)
Lancet Gastroenterol Hepatol. 2022 Jul;7(7):627-647. (PMID: 35397795)
Am J Epidemiol. 2017 May 1;185(9):751-764. (PMID: 28387787)
Med Oncol. 2012 Dec;29(5):3129-35. (PMID: 22752603)
Cancer Causes Control. 2015 Jul;26(7):1047-52. (PMID: 25941065)
Nutrients. 2021 Apr 02;13(4):. (PMID: 33918360)
Oncol Rep. 2003 Nov-Dec;10(6):2015-21. (PMID: 14534736)
Int J Cancer. 2004 Mar;109(1):149-52. (PMID: 14735482)
NPJ Precis Oncol. 2023 Feb 13;7(1):16. (PMID: 36781990)
Biomedicines. 2024 Jan 03;12(1):. (PMID: 38255203)
Cancers (Basel). 2018 Dec 27;11(1):. (PMID: 30591653)
Cancer Causes Control. 2013 Dec;24(12):2129-41. (PMID: 24085585)
Clin Chim Acta. 2007 May 1;380(1-2):24-30. (PMID: 17343838)
Cancer Res. 2012 Oct 15;72(20):5328-37. (PMID: 22926557)
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):401-2. (PMID: 16492937)
Cancer Res. 2010 Jul 1;70(13):5430-7. (PMID: 20516125)
J Epidemiol. 2024 Dec 5;34(12):563-569. (PMID: 38644195)
Front Physiol. 2018 Jun 01;9:640. (PMID: 29910742)
Sci Rep. 2020 Mar 24;10(1):5336. (PMID: 32210264)
Int J Mol Sci. 2024 Feb 16;25(4):. (PMID: 38397015)
Cancer Sci. 2010 May;101(5):1286-91. (PMID: 20331631)
World J Gastroenterol. 2014 May 14;20(18):5177-90. (PMID: 24833848)
Geroscience. 2024 Oct 8;:. (PMID: 39379738)
Syst Rev. 2021 Mar 29;10(1):89. (PMID: 33781348)
Int J Clin Exp Pathol. 2019 Jun 01;12(6):2264-2274. (PMID: 31934050)
Int J Cancer. 2014 Feb 1;134(3):612-21. (PMID: 23824948)
Front Psychol. 2021 Nov 03;12:590320. (PMID: 34803785)
Int J Prev Med. 2020 Sep 03;11:136. (PMID: 33088464)
World J Gastroenterol. 2010 Mar 14;16(10):1252-7. (PMID: 20222170)
Hematol Oncol Clin North Am. 2022 Jun;36(3):393-414. (PMID: 35501176)
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2697-703. (PMID: 18086776)
Cancer Causes Control. 2021 Aug;32(8):871-881. (PMID: 33999316)
BMC Public Health. 2023 Jul 31;23(1):1463. (PMID: 37525147)
BMJ Open Gastroenterol. 2019 Dec 02;6(1):e000339. (PMID: 31875139)
Int Immunol. 2021 Mar 1;33(3):127-148. (PMID: 33337480)
Int J Mol Sci. 2020 May 18;21(10):. (PMID: 32443588)
Front Endocrinol (Lausanne). 2018 Apr 26;9:190. (PMID: 29755407)
J Natl Cancer Inst. 2015 Nov 23;108(4):. (PMID: 26598515)
Clin Cancer Res. 2005 May 15;11(10):3642-6. (PMID: 15897559)
Cancers (Basel). 2023 Jan 12;15(2):. (PMID: 36672434)
World J Gastroenterol. 2012 Jun 14;18(22):2805-12. (PMID: 22719189)
Cancer Med. 2022 Feb;11(4):1145-1159. (PMID: 35048536)
Cancer Prev Res (Phila). 2013 Sep;6(9):875-85. (PMID: 23872505)
Acta Pharm Sin B. 2023 Jun;13(6):2403-2424. (PMID: 37425065)
Front Oncol. 2022 Dec 16;12:1023177. (PMID: 36591515)
J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94. (PMID: 16288122)
Cancer Res. 2012 Jun 15;72(12):3029-37. (PMID: 22511581)
Nutrients. 2021 Jun 19;13(6):. (PMID: 34205356)
Intest Res. 2019 Jul;17(3):404-412. (PMID: 30419640)
BMC Endocr Disord. 2020 May 11;20(1):63. (PMID: 32393372)
Am J Clin Nutr. 2021 Dec 1;114(6):1917-1924. (PMID: 34510172)
Cancer Sci. 2008 Apr;99(4):781-6. (PMID: 18377427)
Biomedicines. 2023 Apr 27;11(5):. (PMID: 37238961)
Metabolism. 2011 Nov;60(11):1530-8. (PMID: 21632074)
Biomed Rep. 2021 Jan;14(1):13. (PMID: 33235728)
Cancer Epidemiol. 2021 Aug;73:101958. (PMID: 34020315)
Transl Oncol. 2021 Oct;14(10):101174. (PMID: 34243011)
Rev Endocr Metab Disord. 2022 Feb;23(1):13-30. (PMID: 34523036)
Am J Epidemiol. 2008 Jul 1;168(1):30-7. (PMID: 18477652)
PLoS One. 2020 Feb 13;15(2):e0229005. (PMID: 32053666)

Keywords: Adipokines; Colorectal Neoplasm; Colorectal Tumors; Obesity; Rectal Neoplasms

0 (Leptin)
0 (Adiponectin)
0 (LEP protein, human)
0 (ADIPOQ protein, human)

Date Created: 20250530 Date Completed: 20250531 Latest Revision: 20250604

20260130

PMC12123994

10.1186/s12885-025-14362-y

40448255